Patents by Inventor Carolyn A. Buser-Doepner

Carolyn A. Buser-Doepner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100324063
    Abstract: The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.
    Type: Application
    Filed: August 5, 2010
    Publication date: December 23, 2010
    Inventors: Carolyn A. Buser-Doepner, Steven J. Freedman, Jackson B. Gibbs, Frank J. Giles, Christopher G. Marshall, John R. Pollard
  • Publication number: 20090227598
    Abstract: The present invention provides methods for inhibiting RET tyrosine kinase. Further, the present invention also provides methods of treating or preventing thyroid cancer.
    Type: Application
    Filed: January 22, 2007
    Publication date: September 10, 2009
    Inventors: Carolyn A. Buser-Doepner, Steven J. Freedman, Cheryl A. Pickett
  • Publication number: 20090105270
    Abstract: This invention relates to novel uses for Compound E in the treatment of diseases, in particular cancer, associated with aberrant kinase expression.
    Type: Application
    Filed: February 19, 2008
    Publication date: April 23, 2009
    Inventor: Carolyn A. Buser-Doepner
  • Publication number: 20090062302
    Abstract: The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.
    Type: Application
    Filed: January 22, 2007
    Publication date: March 5, 2009
    Inventors: Carolyn A. Buser-Doepner, Steven J. Freedman, Jackson B. Gibbs, Frank J. Giles, Christopher G. Marshall, John R. Pollard
  • Publication number: 20090012061
    Abstract: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 8, 2009
    Inventors: Timothy A. Blizzard, Carolyn A. Buser-Doepner, Douglas E. Frantz, Kelly Hamilton, Myle Hoang, Ling Lee, Christopher R. Moyes, Jerry A. Murry, Arash Soheili
  • Publication number: 20060134767
    Abstract: The present invention is directed to the identification, characterization and three-dimensional structure of a novel ligand binding site of KSP. Binding of ligands to the novel binding site result in a conformational change in the three-dimensional structure of the protein and a modulation of the activity of KSP. This conformational change in turn results in the formation of a novel binding pocket in the KSP protein, which comprises the novel binding site of the instant invention.
    Type: Application
    Filed: July 3, 2003
    Publication date: June 22, 2006
    Inventors: Carolyn Buser-Doepner, Paul Coleman, Christopher Cox, Mark Fraley, Robert Garbaccio, George Hartman, David Heimbrook, Lawrence Kuo, Hans Huber, Vinod Sardana, Maricel Torrent, Youwei Yan